Reuters -- Novartis AG (NOVN.VX) (NVS.N) and Astellas Pharma (4503.T) eczema drugs may need their warning labels expanded after dozens of new reported cases of cancer and infection in children, U.S. Food and Drug Administration staff said in documents released on Thursday.